Testosterone Cypionate: The History of Its Development and Medical Use

Testosterone cypionate is the most widely prescribed injectable testosterone in the United States. Its story runs from the isolation of testosterone in the 1930s, through the search for longer-acting esters, to modern debates about who should receive testosterone therapy. Our editorial team traces that history and explains the drug's legitimate place in medicine.

The discovery of testosterone

Interest in the testes as a source of vitality is centuries old, but scientific endocrinology began in the 19th century. In 1889 the physiologist Charles-Édouard Brown-Séquard reported self-injecting testicular extracts and feeling rejuvenated — a claim later attributed largely to placebo, since the extracts contained little active hormone.

The real breakthrough came in 1935. A team led by Ernst Laqueur in Amsterdam isolated a crystalline hormone from bull testes and named it testosterone. Within months, Adolf Butenandt and Leopold Ružička independently described its chemical synthesis from cholesterol-derived precursors.

Butenandt and Ružička shared the 1939 Nobel Prize in Chemistry for their work on sex hormones. Synthetic testosterone could now be produced in quantity, opening the door to clinical research.

Early clinicians quickly ran into a practical problem. Free testosterone injected into the body is metabolized within hours, and taken by mouth it is largely destroyed by the liver before reaching the circulation. A useful medicine needed a way to make the hormone last.

The search for longer-acting esters

Chemists solved the problem by attaching fatty acid chains — esters — to testosterone's 17-beta hydroxyl group. Esterified testosterone dissolves in oil, forms a depot in muscle after injection, and is released slowly as enzymes remove the ester.

Testosterone propionate, introduced in the late 1930s, was the first widely used ester, but its short duration required frequent injections. Over the following decades, longer esters were developed, including testosterone enanthate and testosterone cypionate (cyclopentylpropionate).

Testosterone cypionate was developed by the Upjohn Company and marketed in the US under the brand name Depo-Testosterone, gaining FDA approval in the 1950s era of steroid drug development. Its longer half-life allowed injections at intervals of one to several weeks rather than several times a week.

Cypionate and enanthate are pharmacologically very similar. Cypionate became the dominant ester in American practice, while enanthate has been more common in Europe — a difference rooted largely in commercial history rather than clinical superiority.

Approved medical uses

The FDA-approved indication for testosterone cypionate is testosterone replacement in males with conditions associated with deficient or absent endogenous testosterone. Labeling distinguishes primary hypogonadism (testicular failure) from hypogonadotropic hypogonadism (a problem in the pituitary or hypothalamus).

Conditions that can cause primary hypogonadism include Klinefelter syndrome, undescended testes, orchitis, chemotherapy, and surgical removal of the testes. Secondary causes include pituitary tumors, certain genetic syndromes, and injury.

Testosterone has also been used under specialist care to induce puberty in boys with significantly delayed development. Outside the label, it is a core part of gender-affirming hormone therapy for transgender men, following guidelines from professional societies such as the Endocrine Society.

• Primary hypogonadism (congenital or acquired testicular failure)
• Hypogonadotropic hypogonadism (pituitary or hypothalamic disorders)
• Delayed puberty in selected adolescent boys, under specialist care
• Gender-affirming therapy (guideline-based, off-label)

Diagnosis is supposed to rest on both symptoms and laboratory confirmation. Endocrine Society guidelines recommend measuring morning total testosterone on at least two separate occasions before starting treatment, because levels fluctuate and can be temporarily low due to illness or poor sleep.

Regulation, controversy, and safety labeling

Non-medical use of anabolic steroids among athletes and bodybuilders expanded from the 1960s onward. In response, the US Congress passed the Anabolic Steroid Control Act of 1990, placing testosterone and related compounds in Schedule III of the Controlled Substances Act.

From the early 2000s, testosterone prescriptions rose sharply in the US, driven partly by marketing around "low T" in aging men. Researchers and regulators raised concerns that many men were starting treatment without a confirmed diagnosis.

Several observational studies around 2013–2014 suggested a possible increase in cardiovascular events in some men on testosterone, though results were conflicting. In 2015 the FDA required labeling changes clarifying that testosterone is approved only for hypogonadism caused by specific medical conditions, not age-related decline alone, and noting a possible cardiovascular risk.

The FDA also added warnings about abuse and dependence, and about blood pressure increases with some testosterone products. A large randomized trial, TRAVERSE, published in 2023, found that testosterone therapy in middle-aged and older hypogonadal men with elevated cardiovascular risk was not inferior to placebo for major cardiac events, while noting higher rates of some other events such as atrial fibrillation.

Testosterone cypionate in modern practice

Today, testosterone cypionate remains common because it is inexpensive, widely available as a generic, and has decades of clinical experience behind it. Physicians also prescribe gels, patches, nasal and oral formulations, and long-acting injections such as testosterone undecanoate.

Injectable esters produce peaks and troughs in blood levels between doses, which some patients notice as changes in mood or energy. Choice of formulation depends on patient preference, cost, insurance coverage, and medical factors.

Monitoring is a standard part of therapy. Guidelines recommend checking testosterone levels, hematocrit, and, in appropriate men, prostate-specific antigen at defined intervals, and reassessing whether symptoms have actually improved.

An important consideration is fertility. Exogenous testosterone suppresses sperm production, so men who wish to father children are usually counseled about alternatives before starting therapy.

Conclusions of the editorial team

Testosterone cypionate is the product of nearly a century of endocrine research, born from the need to make a short-lived hormone practical as medicine.

Its legitimate role is the treatment of confirmed hypogonadism and guideline-based hormone therapy, where it is effective and well understood when properly monitored.

The history of regulation shows that the main problems have arisen from use without a clear diagnosis — whether through aggressive marketing or non-medical use.

Readers interested in this area may also want to explore our pieces on the side effects of testosterone propionate, why testosterone may fail to recover after stopping, and the diagnosis of hyperprolactinemia.

References

1. Nieschlag E, Nieschlag S. Endocrine history: the history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212.
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
3. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117.
4. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–1466.
5. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol. 2001;165(2):371–373.
6. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903.